WO1997019690A1 - Stable vancomycin hydrochloride solutions - Google Patents
Stable vancomycin hydrochloride solutions Download PDFInfo
- Publication number
- WO1997019690A1 WO1997019690A1 PCT/US1996/018898 US9618898W WO9719690A1 WO 1997019690 A1 WO1997019690 A1 WO 1997019690A1 US 9618898 W US9618898 W US 9618898W WO 9719690 A1 WO9719690 A1 WO 9719690A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vancomycin hydrochloride
- ethanol
- ppt
- solutions
- vancomycin
- Prior art date
Links
- 108010059993 Vancomycin Proteins 0.000 title claims abstract description 64
- 229960001572 vancomycin hydrochloride Drugs 0.000 title claims abstract description 49
- LCTORFDMHNKUSG-XTTLPDOESA-N vancomycin monohydrochloride Chemical compound Cl.O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 LCTORFDMHNKUSG-XTTLPDOESA-N 0.000 title claims abstract description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 74
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000015556 catabolic process Effects 0.000 claims abstract description 5
- 238000006731 degradation reaction Methods 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 239000013543 active substance Substances 0.000 abstract description 2
- 238000007710 freezing Methods 0.000 abstract description 2
- 230000008014 freezing Effects 0.000 abstract description 2
- 238000003860 storage Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 38
- 229960003165 vancomycin Drugs 0.000 description 15
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 15
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 15
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000003712 Complement factor B Human genes 0.000 description 3
- 108090000056 Complement factor B Proteins 0.000 description 3
- 238000010268 HPLC based assay Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001998 anti-microbiological effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- OGMARHJAPWBNFA-UHFFFAOYSA-N vancomycin cdp-1 Chemical compound O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)CC(C(O)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 OGMARHJAPWBNFA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
Definitions
- This invention relates to aqueous solutions of the antibiotic vancomycin hydrochloride and to a method for improving the stability thereof.
- Vancomycin is described in U.S. Patent No. 3,067,099. It is a well known antibiotic, often prescribed for the treatment of staphylococcal infections, particularly infections caused by methicillin-resistant strains of staphylococcus . Vancomycin is a fermentation product isolated from the culture broth of Norcardia oi entalis , which produces a mixture of closely related co-fermentation factors, "Factor B" being identified as the manor antibacterial agent in the mixture.
- vancomycin itself degrades to a number of products including its predominant degradation product, vancomycin
- Vancomycin is formulated for pharmaceutical use as the hydrochloride salt, vancomycin hydrochloride, which has previously been supplied for oral and parenteral use as a dry- solid or as a frozen liquid preparation.
- liquid solutions of vancomycin hydrochloride have been impractical as pharmaceutical preparations because of the limited stability of the vancomycin hydrochloride agent in solution. Nevertheless, it is desirable to provide vancomycin hydrochloride in solution so as to reduce the manufacturing costs associated with lyophilization and to reduce hospital labor costs required for reconstitution of the lyophilized product and transfer of the reconstituted material .
- the present invention provides stable solutions of vancomycin hydrochloride and a method for inhibiting physical and chemical degradation of vancomycin hydrochloride in a solution.
- the present invention provides stable solutions of vancomycin hydrochloride comprising between about 0.5% and about 12% w/v vancomycin hydrochloride and between about 0.5% and about 30% v/v ethanol. These solutions are particularly useful for storage in a liquid state not requiring either freezing or freeze drying in order to maintain stability of the active agent.
- the present invention also provides a method of inhibiting degradation of vancomycin hydrochloride in a solution containing between about 0.5% and about 12% w/v vancomycin hydrochloride, said method comprising including between about 0.5% and about 30% v/v ethanol in said solution.
- the vancomycin hydrochloride solutions of this invention comprise between about 0.5% and about 12% w/v vancomycin hydrochloride and between about 0.5% and about 30% v/v of ethanol .
- Preferred solutions comprise between about 5% and about 12% w/v vancomycin hydrochloride.
- Solutions comprising between about 10% and 30% v/v ethanol are likewise preferred.
- Especially preferred solutions comprise 10% w/v vancomycin hydrochloride with either 10% or 20% v/v ethanol.
- Especially preferred methods comprise including either 10% or 20% v/v ethanol with 10% w/v vancomycin hydrochloride. Cooling vancomycin hydrochloride solutions containing ethanol to 10°C or less further inhibits degradation of vancomycin and thus results in preferred methods. Temperatures of 0°C to 5°C are especially preferred. Vancomycin hydrochloride solutions of the current invention are prepared by slurrying the calculated amount of vancomycin base in a suitable diluent, for example, water or commercially available preparations used for intravenous administration, in which sufficient alcohol to achieve the desired concentration has been included. Many other suitable diluents are known in the art. Hydrochloric acid is then added to form the soluble hydrochloride salt. The solution of vancomycin hydrochloride is adjusted to a final pH of 2.5- 4.5, preferrably 3.1-3.3 and brought to final volume with the diluent.
- a substantial portion of the hydrochloric acid necessary to convert the base to the salt can be added to a suitable diluent containing sufficient alcohol to achieve the desired concentration prior to adding the vancomycin base.
- the resulting solution is adjusted to a final pH of 2.5-4.5, preferrably 3.1-3.3, and brought to final volume with the diluent.
- the solutions thus prepared are filtered through 0.2 micron membranes to clarify them and render them particulate free. Filtration may also be used to sterilize solutions.
- the filtered solutions can then be filled into a variety of pharmaceutically appropriate packages, such as, for example, ampoules, vials, syringes, and bulk packages.
- Example 1 In order to assess the effect of ethanol on stability of vancomycin hydrochloride solutions, three lots of vancomycin base were converted to vancomycin hydrochloride in a 10% w/v concentrate solution according to the procedures outlined above. Varying concentrations of ethanol were included in the solutions, which were then stored either at room (about 23°C) or refrigerated (about 5°C) temperatures. The solutions were evaluated for purity, retention of potency, appearance of degradation products, and physical stability at various time points.
- vancomycin hydrochloride can be formulated according to the current invention as a liquid that can be easily stored for immediate use.
- vancomycin hydrochloride solutions can be prepared as a concentrate that is readily diluted or as a solution that is ready for direct administration.
- formulations of the current invention may be made sufficiently concentrated to eliminate any concern over the ethanolic content of the diluted product.
- a liquid concentrate containing 100 mg/ml vancomycin hydrochloride and 10% ethanol can be diluted twenty-fold to 5 mg/ml vancomycin hydrochloride and 0.5% ethanol.
- a typical 500 mg dose of vancomycin hydrochloride could be administered in a 100 ml intravenous solution containing 0.5 ml ethanol.
- a 1 g dose of vancomycin hydrochloride could be administered in a 200 ml intravenous solution.
- ethanol occurs at very low ethanol concentrations and may be included in concentrations as low as 0.5% to improve stability of dilute vancomycin hydrochloride solutions.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides stable solutions of vancomycin hydrochloride comprising between about 0.5 % and about 12 % w/v vancomycin hydrochloride and between about 0.5 % and about 30 % v/v ethanol. These solutions are particularly useful for storage in a liquid state not requiring either freezing or freeze drying in order to maintain stability of the active agent. The present invention also provides a method of inhibiting degradation of vancomycin hydrochloride in a solution containing between about 0.5 % and about 12 % w/v vancomycin hydrochloride, said method comprising including between about 0.5 % and about 30 % v/v ethanol in said solution.
Description
Title
STABLE VANCOMYCIN HYDROCHLORIDE SOLUTIONS
This invention relates to aqueous solutions of the antibiotic vancomycin hydrochloride and to a method for improving the stability thereof.
Vancomycin is described in U.S. Patent No. 3,067,099. It is a well known antibiotic, often prescribed for the treatment of staphylococcal infections, particularly infections caused by methicillin-resistant strains of staphylococcus . Vancomycin is a fermentation product isolated from the culture broth of Norcardia oi entalis , which produces a mixture of closely related co-fermentation factors, "Factor B" being identified as the manor antibacterial agent in the mixture.
Few of the co-fermentation factors have been isolated and characterized due to their unstable nature. Moreover, vancomycin itself degrades to a number of products including its predominant degradation product, vancomycin
CDP-1 (see Sheldrick e . al . , Nature 271:223, 1978) . It has been difficult to differentiate between co-fermentation factors and degradation products of vancomycin due to complexity of the chromatographic profile. Vancomycin is formulated for pharmaceutical use as the hydrochloride salt, vancomycin hydrochloride, which has previously been supplied for oral and parenteral use as a dry- solid or as a frozen liquid preparation. Heretofore, liquid solutions of vancomycin hydrochloride have been impractical as pharmaceutical preparations because of the limited stability of the vancomycin hydrochloride agent in solution. Nevertheless, it is desirable to provide vancomycin hydrochloride in solution so as to reduce the manufacturing costs associated with lyophilization and to reduce hospital labor costs required for reconstitution of the lyophilized product and transfer of the reconstituted material .
The present invention provides stable solutions of vancomycin hydrochloride and a method for inhibiting physical and chemical degradation of vancomycin hydrochloride in a solution.
The present invention provides stable solutions of vancomycin hydrochloride comprising between about 0.5% and about 12% w/v vancomycin hydrochloride and between about 0.5% and about 30% v/v ethanol. These solutions are particularly useful for storage in a liquid state not requiring either
freezing or freeze drying in order to maintain stability of the active agent.
The present invention also provides a method of inhibiting degradation of vancomycin hydrochloride in a solution containing between about 0.5% and about 12% w/v vancomycin hydrochloride, said method comprising including between about 0.5% and about 30% v/v ethanol in said solution.
The vancomycin hydrochloride solutions of this invention comprise between about 0.5% and about 12% w/v vancomycin hydrochloride and between about 0.5% and about 30% v/v of ethanol . Preferred solutions comprise between about 5% and about 12% w/v vancomycin hydrochloride. Solutions comprising between about 10% and 30% v/v ethanol are likewise preferred. Especially preferred solutions comprise 10% w/v vancomycin hydrochloride with either 10% or 20% v/v ethanol. The discovery of the benefits provided by inclusion of ethanol in liquid formulations of vancomycin hydrochloride is closely related to a novel method of inhibiting degradation of vancomycin hydrochloride in a solution containing between about 0.5% and about 12% w/v vancomycin hydrochloride, said method comprising including between about 0.5% and about 30% v/v ethanol in said solution. Preferred methods of the current invention comprise the inclusion of between about 5% and about 12% w/v vancomycin hydrochloride, and in particular about 10% w/v vancomycin hydrochloride.
Methods wherein between about 10% and 30% v/v ethanol are included in concentrated solutions of vancomycin hydrochloride are likewise preferred. Especially preferred methods comprise including either 10% or 20% v/v ethanol with 10% w/v vancomycin hydrochloride. Cooling vancomycin hydrochloride solutions containing ethanol to 10°C or less further inhibits degradation of vancomycin and thus results in preferred methods. Temperatures of 0°C to 5°C are especially preferred. Vancomycin hydrochloride solutions of the current invention are prepared by slurrying the calculated amount of vancomycin base in a suitable diluent, for example, water or commercially available preparations used for intravenous administration, in which sufficient alcohol to achieve the desired concentration has been included. Many other suitable diluents are known in the art. Hydrochloric acid is then added to form the soluble hydrochloride salt. The solution of vancomycin hydrochloride is adjusted to a final pH of 2.5- 4.5, preferrably 3.1-3.3 and brought to final volume with the diluent.
Alternatively, a substantial portion of the hydrochloric acid necessary to convert the base to the salt can be added to a suitable diluent containing sufficient alcohol to achieve the desired concentration prior to adding the vancomycin base. The resulting solution is adjusted to a final pH of 2.5-4.5, preferrably 3.1-3.3, and brought to final volume with the diluent.
The solutions thus prepared are filtered through 0.2 micron membranes to clarify them and render them particulate free. Filtration may also be used to sterilize solutions. The filtered solutions can then be filled into a variety of pharmaceutically appropriate packages, such as, for example, ampoules, vials, syringes, and bulk packages.
Example 1 In order to assess the effect of ethanol on stability of vancomycin hydrochloride solutions, three lots of vancomycin base were converted to vancomycin hydrochloride in a 10% w/v concentrate solution according to the procedures outlined above. Varying concentrations of ethanol were included in the solutions, which were then stored either at room (about 23°C) or refrigerated (about 5°C) temperatures. The solutions were evaluated for purity, retention of potency, appearance of degradation products, and physical stability at various time points.
The amount of Factor B remaining in solutions prepared according to the current invention was measured over time by HPLC and is reported in Table 1 as a percent of total vancomycin-related substances. Stability, as measured by retention of potency is reported in Table 2. Appearance of degradation products, recited as related substances, is reported in Table 3.
TABLE 1
Percent Vancomycin Factor B in Vancomycin Hvdrochloride-Ethanol Solutions
Pflys t 2?°C Days at 5°C ot Ethanol Initial 10- 11 24-28 35-40 60-70 60-70 >750
A 0% 96.0 89.7 83.6 PPT 94.6 81.4*
2% 96.0 89.7 85.2 PPT 95.2 83.0
5% 95.8 90.7 86.1 PPT 94.7 83.5
10% 95.8 92.2 88.0 85.3 95.1 84.9
20% 97.0 92.8 90.4 86.6 95.4 87.3
30% 96.1 93.4 91.1 87.8 95.5 88.4
B 0% 95.8 94 .5 90.2 85.9 PPT 95.3 PPT
2% 95.9 94 5 90.1 86.3 PPT 95.5 PPT
5% 96.1 94 .2 90.6 86.8 PPT 95.5 PPT
10% 96.3 94 8 91.8 88.3 88.1 95.8 85.5
20% 96.4 95 1 92.7 89.4 89.6 96.1 87.4
30% 96.4 95 .5 93.7 90.5 91.4 96.1 89.2
C 0% 95.4 90.2 PPT 94.6 PPT
2% 95.3 90.5 85.1 94.6 PPT
5% 95.4 91.8 86.1 94.8 84.1
10% 95.2 91.9 87.5 95.0 86.2
20% 95.2 94.1 88.8 95.1 87.2
30% 95.1 94.3 90.0 95.2 88.4 slight precipitate observed
PPT precipitate present, no HPLC assay performed
TABLE 2
Vancomycin Potency (mσ/ml) of Vancomycin Hydrochloride-Ethanol Solutions
Davs at 23°C Davs at 5°C ot Ethanol Initial 10-11 24-28 35-40 60-70 60-70 >750
A 0% 100.0 95.6 90.9 87.1 80.8* 99.7 85.4*
2% 98.8 95.7 90.3 86.8 82.3* 99.5 87.1
5% 99.8 97.4 93.0 89.2 82.4* 99.8 86.6
10% 98.5 97.4 93.0 91.0 86.2 97.2 89.1
20% 100.0 97.8 95.6 91.5 89.8 99.4 90.1
30% 100.0 98.1 96.5 92.4 90.2 98.7 91.1
B 0% 100.8 98.2 92.5 90.2 85.5* 98.6 PPT
2% 101.8 100.8 93.4 89.8 PPT 99.6 PPT
5% 101.3 98.4 92.8 91.0 PPT 100.4 PPT
10% 102.0 99.0 94.6 90.6 89.1 99.8 90.7
20% 101.7 100.8 94.6 93.8 90.8 99.7 92.6
30% 101.5 100.0 97.0 95.2 92.8 101.6 96.2 c 0% 101.7 95.6 PPT 101.0 PPT
2% 101.6 96.2 91.1 99.8 PPT
5% 104.0 98.0 89.0 101.6 90.6
10% 102.4 97.8 94.3 100.2 92.3
20% 104.0 99.2 93.4 101.4 94.0
30% 103.7 97.7 95.8 101.4 95.4 slight precipitate observed
PPT precipitate present, no HPLC assay performed
TABLE 3
Percent Related Substances (%) in Vancomvcm Hvdrochloride-Ethanol Solutions
Dflys a 23°c. Davs at 5°c
Lot Ethanol Initial 10- -11 24-28 35-40 60-70 60-70 >750
A 0% 0.9 3.3 5.8 PPT 1.6 PPT
2% 0.9 3.4 4.9 PPT 1.5 7.6
5% 0.9 3.2 4.1 PPT 0.9 6.5
10% 0.9 2.7 3.9 3.9 0.9 5.2
20% 0.6 2.4 3.4 3.5 0.9 3.3
30% 0.9 2.1 3.0 3.3 0.9 2.3
B 0% 1.3 2 2 3.7 5.0 PPT 1.6 PPT
2% 1.3 2 1 3.7 4.5 PPT 1.5 PPT
5% 1.2 2 2 3.5 4.3 PPT 1.4 PPT
10% 1.1 1 9 3.2 2.8 3.5 1.3 4.9
20% 0.8 1 7 2.8 2.3 2.4 1.1 3.2
30% 0.8 1 4 2.3 2.1 1.4 0.9 2.0 c 0% 1.1 3.0 PPT 1.4 PPT
2% 1.0 2.8 4.5 1.3 PPT
5% 0.9 2.7 4.1 1.3 6.1
10% 0.8 2.5 3.5 1.2 4.6
20% 0.9 1.1 3.3 1.1 3.2
30% 0.8 0.9 2.9 1.1 2.3
PPT - precipitate present, no HPLC assay performed
The results indicate that addition of ethanol to solutions of vancomycin hydrochloride greatly extends the stability and antimicrobiological activity of the solutions. Thus, vancomycin hydrochloride can be formulated according to the current invention as a liquid that can be easily stored for immediate use. For example, vancomycin hydrochloride solutions can be prepared as a concentrate that is readily diluted or as a solution that is ready for direct administration.
Since the effect of ethanol is concentration dependent, including ethanol at concentrations of about 10%-
30% are preferred and concentrations of 10% and 20% are especially preferred. However, formulations of the current invention may be made sufficiently concentrated to eliminate any concern over the ethanolic content of the diluted product. For example, a liquid concentrate containing 100 mg/ml vancomycin hydrochloride and 10% ethanol can be diluted twenty-fold to 5 mg/ml vancomycin hydrochloride and 0.5% ethanol. A typical 500 mg dose of vancomycin hydrochloride could be administered in a 100 ml intravenous solution containing 0.5 ml ethanol. A 1 g dose of vancomycin hydrochloride could be administered in a 200 ml intravenous solution.
The benefits of ethanol occur at very low ethanol concentrations and may be included in concentrations as low as 0.5% to improve stability of dilute vancomycin hydrochloride solutions.
Claims
1. A solution of vancomycin hydrochloride comprising between about 0.5% and about 12% w/v vancomycin hydrochloride and between about 0.5% and about 30% v/v ethanol .
2. The solution of claim 1 wherein the concentration of vancomycin hydrochloride s about 5% to about 12% w/v.
3. The solution of claim 1 wherein the concentration of vancomycin hydrochloride is about 10% w/v.
4. The solution of claim 1 wherein the concentration of ethanol is between about 10% and about 30% v/v.
5. The solution of claim 1 wherein the concentration of ethanol is about 10% v/v.
6. The solution of claim 3 wherein the concentration of ethanol is about 10% v/v.
7. The solution of claim 3 wherein the concentration of ethanol is about 20% v/v.
8. A method of inhibiting degradation of vancomycin hydrochloride in a solution containing between about 0.5% and about 12% w/v vancomycin hydrochloride, said method comprising including between about 0.5% and about 30% v/v ethanol in said solution.
9. The method of claim 8 wherein the concentration of vancomycin hydrochloride in said solution is about 5% to about 12% w/v.
10. The method of claim 8 wherein the concentration of vancomycin hydrochloride in said solution is about 10% w/v.
11. The method of claim 8 wherein the concentration of ethanol included in said solution is between about 10% and about 30% v/v.
12. The method of claim 8 wherein the concentration of ethanol included in said solution is about 10% v/v.
13. The method of claim 10 wherein the concentration of ethanol is about 10% v/v.
14. The method of claim 10 wherein the concentration of ethanol is about 20% v/v.
15. The method of claim 8 wherein said solution is cooled to 10°C or less.
16. The method of claim 8 wherein said solution is cooled to between about 0°C and about 5°C.
17. The method of claim 13 wherein said solution is cooled to between about 0°C and about 5°C.
18. The method of claim 14 wherein said solution is cooled to between about 0°C and about 5°C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU14071/97A AU1407197A (en) | 1995-12-01 | 1996-11-25 | Stable vancomycin hydrochloride solutions |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US782495P | 1995-12-01 | 1995-12-01 | |
| US60/007,824 | 1995-12-01 | ||
| GBGB9600213.4A GB9600213D0 (en) | 1996-01-05 | 1996-01-05 | Stable vancomycin hydrochloride solutions |
| GB9600213.4 | 1996-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997019690A1 true WO1997019690A1 (en) | 1997-06-05 |
Family
ID=26308428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/018898 WO1997019690A1 (en) | 1995-12-01 | 1996-11-25 | Stable vancomycin hydrochloride solutions |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU1407197A (en) |
| CA (1) | CA2238872A1 (en) |
| WO (1) | WO1997019690A1 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999017793A1 (en) * | 1997-10-03 | 1999-04-15 | Fujisawa Pharmaceutical Co., Ltd. | Hydrochlorides of vancomycin antibiotics and process for producing the same |
| WO2015138983A1 (en) | 2014-03-14 | 2015-09-17 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
| WO2016071495A1 (en) | 2014-11-06 | 2016-05-12 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| WO2016127087A1 (en) * | 2015-02-06 | 2016-08-11 | Latitude Pharmaceuticals, Inc. | Aqueous solution formulations of vancomycin |
| WO2017194385A1 (en) | 2016-05-09 | 2017-11-16 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| WO2020185518A1 (en) | 2019-03-08 | 2020-09-17 | Emphascience, Inc. | Stable pharmaceutical formulations of peptide and protein drugs |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
-
1996
- 1996-11-25 CA CA 2238872 patent/CA2238872A1/en not_active Abandoned
- 1996-11-25 WO PCT/US1996/018898 patent/WO1997019690A1/en active Application Filing
- 1996-11-25 AU AU14071/97A patent/AU1407197A/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4885275A (en) * | 1987-10-15 | 1989-12-05 | Eli Lilly And Company | Vancomycin-HCL solutions and the lyophilization thereof |
Cited By (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999017793A1 (en) * | 1997-10-03 | 1999-04-15 | Fujisawa Pharmaceutical Co., Ltd. | Hydrochlorides of vancomycin antibiotics and process for producing the same |
| US10688046B2 (en) | 2014-03-14 | 2020-06-23 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
| EP4000628A1 (en) * | 2014-03-14 | 2022-05-25 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| US10959949B2 (en) | 2014-03-14 | 2021-03-30 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| JP2017508807A (en) * | 2014-03-14 | 2017-03-30 | キューティスファーマ インコーポレーテッドＣｕｔｉｓｐｈａｒｍａ， Ｉｎｃ． | Compositions and methods for vancomycin oral liquid |
| US11638692B2 (en) | 2014-03-14 | 2023-05-02 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| US10959947B2 (en) | 2014-03-14 | 2021-03-30 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| EP3145527A4 (en) * | 2014-03-14 | 2018-01-03 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
| US10959946B2 (en) | 2014-03-14 | 2021-03-30 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| WO2015138983A1 (en) | 2014-03-14 | 2015-09-17 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
| US10959948B2 (en) | 2014-03-14 | 2021-03-30 | Azurity Pharmaceuticals, Inc. | Composition and method for vancomycin oral liquid |
| US10493028B2 (en) | 2014-03-14 | 2019-12-03 | Cutispharma, Inc. | Composition and method for vancomycin oral liquid |
| US10188697B2 (en) | 2014-11-06 | 2019-01-29 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| US11517609B2 (en) | 2014-11-06 | 2022-12-06 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| WO2016071495A1 (en) | 2014-11-06 | 2016-05-12 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| EP3542812A1 (en) | 2014-11-06 | 2019-09-25 | Xellia Pharmaceuticals ApS | Glycopeptide compositions |
| EP3834837A1 (en) | 2014-11-06 | 2021-06-16 | Xellia Pharmaceuticals ApS | Glycopeptide compositions |
| US11000567B2 (en) | 2014-11-06 | 2021-05-11 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| US10039804B2 (en) | 2014-11-06 | 2018-08-07 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| US10849956B2 (en) | 2014-11-06 | 2020-12-01 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| EP4147710A1 (en) | 2014-11-06 | 2023-03-15 | Xellia Pharmaceuticals ApS | Glycopeptide compositions in solution |
| US11628200B2 (en) | 2014-11-06 | 2023-04-18 | Xellia Pharmaceuticals Aps | Glycopeptide compositions |
| US12161690B2 (en) | 2014-11-06 | 2024-12-10 | Hikma Pharmaceuticals Usa Inc. | Glycopeptide compositions |
| AU2016215070B2 (en) * | 2015-02-06 | 2020-09-24 | Latitude Pharmaceuticals, Inc. | Aqueous solution formulations of vancomycin |
| JP2018507848A (en) * | 2015-02-06 | 2018-03-22 | ラティチュード ファーマシューティカルズ インコーポレイテッド | Vancomycin aqueous formulation |
| US10376560B2 (en) | 2015-02-06 | 2019-08-13 | Latitude Pharmaceuticals, Inc. | Aqueous solution formulations of vancomycin |
| WO2016127087A1 (en) * | 2015-02-06 | 2016-08-11 | Latitude Pharmaceuticals, Inc. | Aqueous solution formulations of vancomycin |
| CN107106585A (en) * | 2015-02-06 | 2017-08-29 | 杭州美南医药科技有限公司 | the aqueous solution preparation of vancomycin |
| US10729708B2 (en) | 2016-05-09 | 2020-08-04 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| WO2017194385A1 (en) | 2016-05-09 | 2017-11-16 | Xellia Pharmaceuticals Aps | Stabilized glycopeptide antibiotic formulations |
| CN109069580A (en) * | 2016-05-09 | 2018-12-21 | 埃克斯利亚制药有限公司 | Stabilized glycopeptide antibiotic preparation |
| WO2020185518A1 (en) | 2019-03-08 | 2020-09-17 | Emphascience, Inc. | Stable pharmaceutical formulations of peptide and protein drugs |
| US11433115B2 (en) | 2020-10-30 | 2022-09-06 | Somerset Therapeutics, Llc | Glycopeptide antibiotics liquid formulations and methods and uses thereof |
| EP4014965A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
| WO2022129263A1 (en) | 2020-12-16 | 2022-06-23 | Ever Valinject Gmbh | Aqueous solution |
| WO2022129264A1 (en) | 2020-12-16 | 2022-06-23 | Ever Valinject Gmbh | Aqueous solution |
| EP4014969A1 (en) | 2020-12-16 | 2022-06-22 | EVER Valinject GmbH | Aqueous solution |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2238872A1 (en) | 1997-06-05 |
| AU1407197A (en) | 1997-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6239167B2 (en) | Lipopeptide composition and related methods | |
| PT1586580E (en) | Process for the purification of daptomycin | |
| WO1997019690A1 (en) | Stable vancomycin hydrochloride solutions | |
| US6949509B2 (en) | Pharmaceutical composition containing a small or medium size peptide | |
| US4670258A (en) | Storable prepackaged aqueous solutions of vancomycin | |
| JP3361830B2 (en) | Antimicrobial composition and drug containing the same as active ingredient | |
| US5714458A (en) | Stable pharmaceutical compositions containing a fibroblast growth factor | |
| US5776912A (en) | Lipophilic oligosaccharide antibiotic compositions | |
| EP0539408B1 (en) | Stable pharmaceutical compositions containing a fibroblast growth factor | |
| Perronne et al. | Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination | |
| SK53597A3 (en) | A storage stable water solution for infusion containing a thrombin inhibitor | |
| IL147755A (en) | Multidose erythropoietin formulations with benzethonium chloride as an inhibitor of microbial growth | |
| IL129607A (en) | Stabilized pharmaceutical compositions based on quinupristine and on dalfopristine and process for their preparation | |
| HU193217B (en) | Process for producing active agents for immunemodulator compositions | |
| CA1285226C (en) | Compositions containing a 2,4-diamino-pyrimidine and sulphadimidine | |
| US20040043980A1 (en) | Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers | |
| US5089478A (en) | Method for the control of pneumocystis carinii | |
| EP1121935A1 (en) | Pharmaceutical composition containing a small or medium size peptide | |
| WO2024079223A1 (en) | Liquid dalbavancin composition | |
| Wise et al. | Activity, stability, and pharmacology of the epimers of moxalactam | |
| US20060252915A1 (en) | Antimicrobial bolisin peptides | |
| AU2006235847C1 (en) | Lyophilized pantoprazole preparation | |
| JPH0688904B2 (en) | Growth inhibitor against virus | |
| Al | Treatment of Staphylococcus aureus Endocarditis in Rats with Coumermycin Al and Ciprofloxacin, Alone or in Combination | |
| JPH06211687A (en) | Suppressor for cytomegalovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref document number: 2238872 Country of ref document: CA Ref country code: CA Ref document number: 2238872 Kind code of ref document: A Format of ref document f/p: F |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 97520604 Format of ref document f/p: F |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase |